Amicus Therapeutics (FOLD) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FOLD shares.
View FOLD analyst ratings or view top-rated stocks.

5 equities research analysts have issued 12-month target prices for Amicus Therapeutics' shares. Their FOLD share price forecasts range from $11.00 to $17.00. On average, they expect the company's share price to reach $15.20 in the next twelve months. This suggests a possible upside of 32.2% from the stock's current price.
View analysts price targets for FOLD or view top-rated stocks among Wall Street analysts.

Amicus Therapeutics' stock was trading at $12.21 at the beginning of 2023. Since then, FOLD stock has decreased by 5.8% and is now trading at $11.50.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our FOLD earnings forecast.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.03. The biopharmaceutical company earned $94.50 million during the quarter, compared to the consensus estimate of $89.57 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 157.79% and a negative net margin of 52.85%.

ETFs with the largest weight of Amicus Therapeutics (NASDAQ:FOLD) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), Global X Guru Index ETF (GURU), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC).

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Amicus Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.34%), JPMorgan Chase & Co. (4.72%), State Street Corp (3.89%), Point72 Asset Management L.P. (2.44%), Geode Capital Management LLC (1.90%) and Fiera Capital Corp (1.75%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Hung Do, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends.

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FOLD stock can currently be purchased for approximately $11.50.

Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.30 billion and generates $329.23 million in revenue each year. The biopharmaceutical company earns $-236,570,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

The company employs 484 workers across the globe.

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for the company is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001.